Calando

Still, the company is uncertain when it will meet this goal and has put all partnership talks on hold, according to an official from Calando's parent firm Arrowhead Research.

According to Arrowhead President and CEO Christopher Anzalone, the data are expected to bolster the company's efforts to either divest or find a partner for Calando — a longstanding corporate goal — but he said that specific details about the clinical results were not yet being disclosed.

Overview of key RNAi-based therapeutics currently in human trials

Earlier this year, Arrowhead announced that it had closed Calando’s laboratory and shifted all its development efforts onto another of its subsidiaries. But with this week’s announcement, it appears that Arrowhead has decided to give its lead RNAi cancer therapeutic a second chance.

People in the News

Premium

James Hamilton, Mostafa Analoui, Bruce Given, Kenneth Berlin

The company said it has been given 180 days, until March 15, 2010, to regain compliance by maintaining a minimum closing bid price of $1 per share for 10 consecutive business days.

While many firms have successfully met their goals of allying with big pharmas and biotechs, others have failed to do so, despite promises of forthcoming deals.

Meanwhile, in a filing with the US Securities and Exchange Commission, Arrowhead warned that its fiscal 2009 operating losses and negative cash flows from operations "raises doubts about its ability to continue as a going concern over the next 12 months and beyond."

The company is planning to sell 7.1 million units, which comprise one share of common stock and a warrant to purchase an additional share.

People in the News

Premium

Steven Rubin, Peter Garcia, Bruce York, Paul McDonnel, Joseph Kingsley

Pages

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.